Aller au contenu principal
Profil bibliographique

Michiko Koga

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

20Publications signalées
465Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections StudiesHepatitis C virus researchBacillus and Francisella bacterial researchSARS-CoV-2 detection and testing

Les publications récentes

Accès ouvert 2025 article OpenAlex

Enhancer of zeste homolog 1/2 dual inhibitor valemetostat outperforms enhancer of zeste homolog 2-selective inhibitors in reactivating latent HIV-1 reservoirs ex vivo

Ayako Sedohara, Tomohiko Koibuchi, Makoto Yamagishi, Michiko Koga et autres

For the eradication of human immunodeficiency virus type 1 (HIV-1) provirus from people living with HIV-1, reactivation of latently HIV-1-infected cells is essential. Although several latency reversing agents have been identified, eradication of HIV-infected cells has been a challenge. Here, we investigated …

jp, de (code pays fourni par la source)

1 citation Frontiers in Microbiology
Accès ouvert 2025 article OpenAlex

Amino acid substitutions in NSP6 and NSP13 of SARS-CoV-2 contribute to superior virus growth at low temperatures

Yuri Furusawa, Maki Kiso, Ryuta Uraki, Yuko Sakai‐Tagawa et autres

ABSTRACT In general, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replicates well at 37°C, which is the temperature of the human lower respiratory tract, but it poorly at 30°C‒32°C, which is the temperature of the human upper respiratory tract. The replication efficiency …

jp, us, Ouganda (code pays fourni par la source)

1 citation Journal of Virology
Accès ouvert 2025 article OpenAlex

Psychological support for people with hemophilia and HIV who suffer from cancer: A first national survey

Akari Fukuda, Michiko Koga, Takahiro Tanaka, Aya Ishizaka et autres

Psychological support is necessary for people with hemophilia and HIV (PHH) who suffer from cancers. Most PHH are infected with not only HIV but also hepatitis C virus due to non-heat-treated blood coagulation factor products. PHH have a high risk of carcinogenesis, …

jp (code pays fourni par la source)

0 citations Global Health & Medicine
Accès ouvert 2025 article OpenAlex

MicroRNA in neuroexosome as a potential biomarker for HIV-associated neurocognitive disorders

Kotaro Arizono, Ayako Sedohara, Khulan Tuvshinjargal, Takahiro Tanaka et autres

HIV-associated neurocognitive disorder (HAND) is a complication of chronic inflammation caused by HIV infection that impairs cognitive and motor functions. HAND can occur at any age, regardless of the duration of infection, even in people living with HIV (PLWH) whose blood viral …

jp, us (code pays fourni par la source)

5 citations Journal of NeuroVirology
Accès ouvert 2024 article OpenAlex

Dysbiosis of gut microbiota in COVID-19 is associated with intestinal DNA phage dynamics of lysogenic and lytic infection

Aya Ishizaka, Azumi Tamura, Michiko Koga, Taketoshi Mizutani et autres

ABSTRACT This study compared intestinal DNA phage dynamics and gut microbiota changes observed at the onset of coronavirus disease 2019 (COVID-19). The study participants included 19 healthy individuals and 19 patients with severe acute respiratory syndrome coronavirus 2 infection. Significant differences were …

us, jp (code pays fourni par la source)

2 citations Microbiology Spectrum
Accès ouvert 2024 article OpenAlex

Non-acquired immunodeficiency syndrome defining malignancies in people living with haemophilia and human immunodeficiency virus after direct-acting antiviral era

Michiko Koga, Akari Fukuda, Masanori Nojima, Aya Ishizaka et autres

Non-acquired immunodeficiency syndrome-defining malignancies (NADMs) are the crucial cause of mortality in people living with haemophilia and human immunodeficiency virus (PLWHH). We aimed to analyse the types and characters of NADMs in PLWHH after approval of direct-acting antivirals (DAA), considering that most …

us, jp (code pays fourni par la source)

2 citations Global Health & Medicine
Accès ouvert 2024 article OpenAlex

Hepatitis B Virus Reactivation After Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi et autres

A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine/tenofovir alafenamide to cabotegravir/rilpivirine. An immune escape …

jp (code pays fourni par la source)

24 citations Emerging infectious diseases
Accès ouvert 2023 article OpenAlex

Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine

Thomas Cleven, Ralph S. Baric, Shinya Yamamoto, Ryuta Uraki et autres

Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine-induced memory T cells limits lung SARS-CoV-2 replication and severe disease. We show that mice …

us (code pays fourni par la source)

0 citations Carolina Digital Repository (University of North Carolina at Chapel Hill)
Accès ouvert 2023 article OpenAlex

Airway surveillance and lung viral control by memory T cells induced by COVID-19 mRNA vaccine

Brock Kingstad-Bakke, Thomas Cleven, Hailey E. Bussan, Boyd L. Yount et autres

Although SARS-CoV-2 evolution seeds a continuous stream of antibody-evasive viral variants, COVID-19 mRNA vaccines provide robust protection against severe disease and hospitalization. Here, we asked whether mRNA vaccine-induced memory T cells limit lung SARS-CoV-2 replication and severe disease. We show that mice …

us, jp, hr (code pays fourni par la source)

14 citations JCI Insight
Accès ouvert 2023 article OpenAlex

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate

Ryuta Uraki, Mutsumi Ito, Maki Kiso, Seiya Yamayoshi et autres

The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs …

jp, us (code pays fourni par la source)

9 citations iScience

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.